Purpose: To illustrate treatment frequency dynamics with patient case profiles from the identical phase 3 YOSEMITE/RHINE (NCT03622580/NCT03622593) trials of faricimab (a bispecific antibody designed to inhibit angiopoietin-2 and vascular endothelial growth factor-A). Durability of faricimab effect in the personalised treatment interval (PTI) arm was a key objective of YOSEMITE/ RHINE. Methods: Diabetic macular oedema patients from YOSEMITE/RHINE received either faricimab 6.0 mg every eight weeks (Q8W, n = 630), faricimab 6.0 mg PTI (n = 632) or aflibercept 2.0 mg Q8W (n = 626). The PTI algorithm is a protocol-driven regimen based on the treat-and-extend concept; dosing intervals were adjusted in 4-week increments (up to Q16W) using pre-specified central subfield thickness and visual acuity criteria. Achievement of treatment intervals (Q4W, Q8W, Q12W or Q16W) and additional anatomical endpoints were assessed at week 52. Results: In YOSEMITE/RHINE, faricimab demonstrated non-inferior vision gains compared to aflibercept (faricimab Q8W: 10.7/11.8; faricimab PTI: 11.6/10.8; aflibercept: 10.9/10.3 letters), improved anatomic outcomes (mean central subfield thickness change: faricimab Q8W: -206.6/-195.8; faricimab PTI: -196.5/-187.6; aflibercept: -170.3/-170.1 μm), and extended dosing potential at year 1. Week 52 PTI treatment intervals and proportion of patients achieving them were: Q16W (>50), ≥Q12W (>70), Q8W (16) and Q4W (12). Representative cases and associated retinal images of PTI dosing dynamics (baseline-week 52) will be presented. Conclusion: This post-hoc analysis of individualised treatment frequency dynamics illustrates how the faricimab PTI algorithm was used effectively to optimise treatment intervals according to heterogeneous needs of patients with diabetic macular oedema. Faricimab PTI arm demonstrated durability of faricimab effect, with ~52 of patients on Q16W and ~72 on ≥Q12W treatment intervals at week 52.
展开▼
